vc-mmae adcs Search Results


90
Genentech inc vc-mmae adcs
ADCs, targets, and tumor indications of eight <t> vc-MMAE ADCs </t> included in the analysis.
Vc Mmae Adcs, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vc-mmae+adcs/vc+mmae+adcs/pmc06927763-53-8-4
Average 90 stars, based on 1 article reviews
vc-mmae adcs - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Genentech inc vcmmae adcs
ADCs, targets, and tumor indications of eight <t> vc-MMAE ADCs </t> included in the analysis.
Vcmmae Adcs, supplied by Genentech inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vc-mmae+adcs/vcmmae+adcs/pm27773754-103-3-3
Average 90 stars, based on 1 article reviews
vcmmae adcs - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Frontage Laboratories interchain cysteine-linked adcs (igg1 mab-vcmmae) with an average dar of 3.80
ADCs, targets, and tumor indications of eight <t> vc-MMAE ADCs </t> included in the analysis.
Interchain Cysteine Linked Adcs (Igg1 Mab Vcmmae) With An Average Dar Of 3.80, supplied by Frontage Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vc-mmae+adcs/interchain+cysteine+linked+adcs++igg1+mab+vcmmae++with+an+average+dar+of+3+80/pm31872274-51-8-19
Average 90 stars, based on 1 article reviews
interchain cysteine-linked adcs (igg1 mab-vcmmae) with an average dar of 3.80 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


ADCs, targets, and tumor indications of eight  vc-MMAE ADCs  included in the analysis.

Journal: mAbs

Article Title: Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies

doi: 10.1080/19420862.2019.1699768

Figure Lengend Snippet: ADCs, targets, and tumor indications of eight vc-MMAE ADCs included in the analysis.

Article Snippet: Over the past decade, Genentech has developed eight vc-MMAE ADCs, against different targets and for diverse tumor indications, which provides a unique opportunity to characterize the clinical pharmacology for this class of ADCs.

Techniques:

PK parameters (mean ± SD [%CV]) of acMMAE, total antibody and unconjugated MMAE post the first dose of  vc-MMAE ADCs  at 2.4 mg/kg (90 min IV infusion).

Journal: mAbs

Article Title: Clinical pharmacology of vc-MMAE antibody–drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies

doi: 10.1080/19420862.2019.1699768

Figure Lengend Snippet: PK parameters (mean ± SD [%CV]) of acMMAE, total antibody and unconjugated MMAE post the first dose of vc-MMAE ADCs at 2.4 mg/kg (90 min IV infusion).

Article Snippet: Over the past decade, Genentech has developed eight vc-MMAE ADCs, against different targets and for diverse tumor indications, which provides a unique opportunity to characterize the clinical pharmacology for this class of ADCs.

Techniques: